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Fig. 1d-f, a significantly (p < 0.01) higher dose was delivered 
to RILD patients nearby the basal portion of the right lung 
and the submantellar region of the left lung. The average 
dose delivered to this volume (9.4% of the lungs) was of 5.3 
Gy in RILD patients and 2.6 Gy in non-RILD patients. 
 
 
 
Conclusion: By a VB approach we were able to highlight local 
dose-RILD relationship in the lungs. Interestingly, a 
significantly different dose was delivered in the low-dose (~ 5 
Gy) parenchymal regions, in agreement with previous DVH 
analyses showing that the volume exceeding 5 Gy is 
consistently more predictive than other dosimetric variables. 
In order to obtain more powerful insights on local lung 
radiosensitivity, this preliminary results should be enriched 
by applying the VB approach to larger databases evaluating 
RILF in heterogeneously treated lungs. 
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Purpose or Objective: Particle therapy has the potential to 
improve radiotherapy due to the increase in dose conformity 
and RBE. The RBE depends on multiple factors including cell 
type, dose, particle type and energy. Accordingly, a variable 
RBE is clinically applied for carbon ion therapy, in contrast to 
a prescribed constant RBE = 1.1 in proton therapy 
jeopardizing part of its accuracy. Therefore, it is the aim to 
enhance proton therapy by translating a more realistic RBE 
description into the clinic directly based on clinical (and 
preclinical) experience gained with photons and heavier ions 
such as helium and carbon ions. 
 
Material and Methods: The RBE is considered to depend on a) 
the dose response of the biological endpoint and b) the 
heterogeneity of the dose distribution on the cellular level 
(similar to the local effect model). The heterogeneity is 
determined by the clinically accessible (prescribed) dose D 
and the beam quality Q = Z²/E (varying within the patient), 
where Z and E are the ion charge and kinetic energy, 
respectively. We propose an approach to obtain proton RBE 
by interpolating between the biological effectiveness of a 
homogeneous dose distribution for photons and an 
increasingly heterogeneous distribution for heavier and 
slower ions. Based on the linear-quadratic (LQ) model and 
the dose heterogeneity an analytical description of the 
radiobiological effect was derived. It suggests a linear 
increase of the LQ parameter for particle irradiation αP with 
beam quality Q. In vitro RBE data from the literature for 
different ion types, cell lines, and within clinically relevant 
LET ranges (below the RBE maximum) were analyzed. 
 
Results: The considered RBE data seem to depend directly on 
beam quality Q (Figure 1a). In contrast, particle type 
together with LET appear as a surrogate for beam quality Q 
(Figure 1b). In accordance with the derived description, the 
LQ parameter αP increases linearly with Q (Figure 1c) and the 
RBE (Figure 1d) as well as αP could be approximated for all 
considered ions and cell lines with a simple formula 
depending on Q, D, and the photon LQ parameters αX and βX. 
The deviations between prediction and experiment are 
mostly within 10 - 20% and therefore on the order of 
uncertainties often associated with RBE experiments. The 
variation of βP with Q was much weaker and less conclusive. 
 
 
 
Conclusion: As long as cells “experience” a comparable 
microscopic dose distribution they cannot distinguish 
between different ion beams confirming that RBE variability 
also exists in proton therapy. More realistic RBE values for 
proton therapy may be directly obtained from available 
empirical RBE data for heavier ions considering the same 
beam quality Q and endpoint or, alternatively, by 
interpolating between empirical data from photon irradiation 
and heavier ions. Experimental preclinical (and clinical) data 
should be gathered in order to validate the proposed strategy 
to enhance proton therapy. 
 
 
 
 
 
 
